Elanco Animal Health Inc 8-K

What Happened

• Elanco Animal Health Inc. held its annual meeting on May 21, 2026 and filed an 8-K on May 27, 2026 reporting the voting results. All board nominees were elected to one-year terms ending at the 2027 annual meeting.
  • Class I nominees: Kapila K. Anand — For 375,459,071; Against 91,840,502; Abstain 655,918; Broker non-votes 15,365,167. Paul Herendeen — For 441,252,058; Against 26,575,629; Abstain 127,804; Broker non-votes 15,365,167.
  • Class II nominees: Michael Harrington — For 373,406,333; Against 94,421,261; Abstain 127,897; Broker non-votes 15,365,167. Lawrence Kurzius — For 442,964,897; Against 24,863,542; Abstain 127,052; Broker non-votes 15,365,167. Kirk McDonald — For 440,842,458; Against 26,978,663; Abstain 134,370; Broker non-votes 15,365,167.
• Shareholders ratified Ernst & Young LLP as Elanco’s independent registered public accounting firm for 2026 (For 480,470,647; Against 2,611,450; Abstain 238,561).
• The non-binding “say-on-pay” vote approving executive compensation passed (For 383,528,222; Against 84,173,798; Abstain 253,471; Broker non-votes 15,365,167).

Key Details

• Annual meeting date: May 21, 2026; 8-K filed May 27, 2026.
• All five board nominees were elected to one-year terms through the 2027 annual meeting.
• Auditor ratification: Ernst & Young LLP received ~480.5 million votes in favor (approx. 99% of votes cast on that item).
• Say-on-pay: ~383.5 million votes in favor vs ~84.2 million against (about 82% of votes cast in favor).

Why It Matters

• Board continuity: Re-election of all nominees keeps the current board in place for another year, which affects strategic oversight and corporate governance continuity.
• Audit continuity: Ratification of Ernst & Young LLP means Elanco will continue with the same independent auditor for 2026, important for ongoing financial reporting and audit planning.
• Shareholder sentiment on pay: The say-on-pay vote passed by a clear majority, but a substantial minority opposed it (roughly 18%), which investors and management may monitor as a signal of shareholder views on executive compensation.
• No executive appointments, departures or other material corporate actions were disclosed in this filing beyond the voting results.